Discovery of 1-(1,3,5-triazin-2-yl)piperidine-4-carboxamides as inhibitors of soluble epoxide hydrolase
โ Scribed by Thalji, Reema K.; McAtee, Jeff J.; Belyanskaya, Svetlana; Brandt, Martin; Brown, Gregory D.; Costell, Melissa H.; Ding, Yun; Dodson, Jason W.; Eisennagel, Steve H.; Fries, Rusty E.; Gross, Jeffrey W.; Harpel, Mark R.; Holt, Dennis A.; Israel, David I.; Jolivette, Larry J.; Krosky, Daniel; Li, Hu; Lu, Quinn; Mandichak, Tracy; Roethke, Theresa; Schnackenberg, Christine G.; Schwartz, Benjamin; Shewchuk, Lisa M.; Xie, Wensheng; Behm, David J.; Douglas, Stephen A.; Shaw, Ami L.; Marino, Joseph P.
- Book ID
- 120894190
- Publisher
- Elsevier Science
- Year
- 2013
- Tongue
- English
- Weight
- 819 KB
- Volume
- 23
- Category
- Article
- ISSN
- 0960-894X
No coin nor oath required. For personal study only.
๐ SIMILAR VOLUMES
1-(1-Acetyl-piperidin-4-yl)-3-adamantan-1-yl-urea 14a (AR9281), a potent and selective soluble epoxide hydrolase inhibitor, was recently tested in a phase 2a clinical setting for its effectiveness in reducing blood pressure and improving insulin resistance in pre-diabetic patients. In a mouse model
## Abstract The synthesis of the clinical candidate (I) and its analogues is achieved via a library approach allowing the facile preparation of various left hand side and right hand side combinations around the piperidinyl urea nucleus.